You just read:

Ibrutinib (IMBRUVICA®) Significantly Improved Progression-Free and Overall Survival Versus Chlorambucil in Patients with Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

News provided by

Janssen Research & Development, LLC

Dec 06, 2015, 11:05 ET